Literature DB >> 9780256

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract.

B Ferko1, D Katinger, A Grassauer, A Egorov, J Romanova, B Niebler, H Katinger, T Muster.   

Abstract

Previously, a mucosal model of immunization against human immunodeficiency virus type 1 (HIV-1) was established by using influenza virus as a vector for the neutralizing gp41 epitope ELDKWA. Whether replication of this chimeric influenza virus in the upper respiratory tract of mice is sufficient for inducing mucosal immune responses in the genital tract was investigated. An immunization strategy was established that permits the virus to replicate in the murine upper respiratory tracts but not in the lungs. Intranasal application of the chimeric virus induced HIV-1-specific antibodies in sera and genital tract. In addition, chimeric virus-specific antibody-secreting cells were detected in lymphocyte populations obtained from lungs, spleens, and urogenital tracts. These results indicate that replication of the chimeric influenza/ELDKWA virus in the upper respiratory tract is sufficient to induce systemic immune responses as well as local immune responses in the genital tract.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780256     DOI: 10.1086/314445

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 2.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

3.  Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Authors:  Sabine Sereinig; Marina Stukova; Natalia Zabolotnyh; Boris Ferko; Christian Kittel; Julia Romanova; Tatiana Vinogradova; Hermann Katinger; Oleg Kiselev; Andrej Egorov
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.

Authors:  Zhu-Nan Li; Scott N Mueller; Ling Ye; Zhigao Bu; Chinglai Yang; Rafi Ahmed; David A Steinhauer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Authors:  Eloisa Yuste; Hannah B Sanford; Jill Carmody; Jacqueline Bixby; Susan Little; Michael B Zwick; Tom Greenough; Dennis R Burton; Douglas D Richman; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Authors:  Christian Kittel; Boris Ferko; Martina Kurz; Regina Voglauer; Sabine Sereinig; Julia Romanova; Gabriela Stiegler; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice.

Authors:  B Ferko; J Stasakova; S Sereinig; J Romanova; D Katinger; B Niebler; H Katinger; A Egorov
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Authors:  M Magdalena Gherardi; José Luis Nájera; Eva Pérez-Jiménez; Susana Guerra; Adolfo García-Sastre; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Authors:  Steve Bryson; Jean-Philippe Julien; Rosemary C Hynes; Emil F Pai
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.